BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11665725)

  • 1. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
    Galitz J
    Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciclopirox nail lacquer: a brush with onychomycosis.
    Gupta AK
    Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
    Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
    J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
    Gupta AK; Joseph WS
    J Am Podiatr Med Assoc; 2000; 90(10):495-501. PubMed ID: 11107710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
    Brenner MA; Harkless LB; Mendicino RW; Page JC
    J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
    Bohn M; Kraemer K
    J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciclopirox nail lacquer and podiatric practice.
    Gupta AK; Malkin KF
    J Am Podiatr Med Assoc; 2000; 90(10):502-7. PubMed ID: 11107711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
    Seebacher C; Nietsch KH; Ulbricht HM
    Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciclopirox nail lacquer solution 8% in the 21st century.
    Gupta AK; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
    Gupta AK; Fleckman P; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciclopirox nail lacquer topical solution 8%.
    Gupta AK
    Skin Therapy Lett; 2000; 6(1):1-5. PubMed ID: 11027420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
    Gupta AK; Schouten JR; Lynch LE
    Skin Therapy Lett; 2005 Sep; 10(7):1-3. PubMed ID: 16292454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
    Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
    Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.
    Friedlander SF; Chan YC; Chan YH; Eichenfield LF
    Pediatr Dermatol; 2013; 30(3):316-22. PubMed ID: 23278851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
    Schalka S; Nunes S; Gomes Neto A
    An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A-Detail fact sheet (Canada). Ciclopirox 8% nail lacquer (Penlac).
    Skin Therapy Lett; 2005 Dec-2006 Jan; 10(10):suppl 1 p.. PubMed ID: 16518906
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
    Baran R; Kaoukhov A
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
    Ulbricht H; Wörz K
    Mycoses; 1994; 37 Suppl 1():97-100. PubMed ID: 7854374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.